CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care
August 29th 2023Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Read More
Dr. Subudhi Discusses Rationale for CheckMate-650 Study in Prostate Cancer
February 21st 2019Sumit K. Subudhi, MD, PhD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale for the CheckMate-650 study in the treatment of patients with metastatic castration-resistant prostate cancer.
Read More